Apellis Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary: Apellis Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q2 2024.
Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$37.7M, a 69.1% increase year-over-year.
Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$333M, a 49.3% increase year-over-year.
Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$529M, a 18.9% increase from 2022.
Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$652M, a 12.6% increase from 2021.
Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$746M, a 116% decline from 2020.

Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)

Net Income (Loss) Attributable to Parent, Quarterly (USD)

Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	-$333M	-$37.7M	+$84.4M	+69.1%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-01
Q1 2024	-$417M	-$66.4M	+$111M	+62.6%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-08-01
Q4 2023	-$529M	-$88.6M	+$77.4M	+46.6%	Oct 1, 2023	Dec 31, 2023	10-K/A	2024-02-29
Q3 2023	-$606M	-$140M	+$51M	+26.7%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-01
Q2 2023	-$657M	-$122M	+$33.9M	+21.8%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-01
Q1 2023	-$691M	-$178M	-$38.8M	-28%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-08-01
Q4 2022	-$652M	-$166M	-$18.1M	-12.2%	Oct 1, 2022	Dec 31, 2022	10-K/A	2024-02-29
Q3 2022	-$634M	-$191M	+$4.3M	+2.2%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-01
Q2 2022	-$638M	-$156M	+$63.2M	+28.8%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-11-01
Q1 2022	-$702M	-$139M	+$44.7M	+24.4%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-11-01
Q4 2021	-$746M	-$148M	-$226M	-289%	Oct 1, 2021	Dec 31, 2021	10-K/A	2024-02-29
Q3 2021	-$520M	-$196M	-$59.9M	-44.1%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-07
Q2 2021	-$460M	-$219M	-$101M	-84.8%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-11-07
Q1 2021	-$360M	-$184M	-$14.8M	-8.79%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-11-07
Q4 2020	-$345M	$78.3M	+$191M		Oct 1, 2020	Dec 31, 2020	10-K	2021-02-25
Q3 2020	-$536M	-$136M	-$65.9M	-94.3%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-08
Q2 2020	-$470M	-$119M	-$47.5M	-66.9%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-11-08
Q1 2020	-$423M	-$169M	-$118M	-234%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-11-08
Q4 2019	-$305M	-$113M	-$76.8M	-211%	Oct 1, 2019	Dec 31, 2019	10-K	2021-02-25
Q3 2019	-$228M	-$69.8M	-$33.9M	-94.1%	Jul 1, 2019	Sep 30, 2019	10-K	2021-02-25
Q2 2019	-$194M	-$71.1M	-$37.8M	-113%	Apr 1, 2019	Jun 30, 2019	10-K	2021-02-25
Q1 2019	-$156M	-$50.6M	-$28.8M	-133%	Jan 1, 2019	Mar 31, 2019	10-K	2021-02-25
Q4 2018	-$128M	-$36.5M	-$18.2M	-99.7%	Oct 1, 2018	Dec 31, 2018	10-K	2020-02-27
Q3 2018	-$109M	-$36M	-$24.4M	-211%	Jul 1, 2018	Sep 30, 2018	10-K	2020-02-27
Q2 2018	-$84.9M	-$33.3M	-$21.2M	-175%	Apr 1, 2018	Jun 30, 2018	10-K	2020-02-27
Q1 2018	-$63.7M	-$21.7M	-$12.7M	-140%	Jan 1, 2018	Mar 31, 2018	10-K	2020-02-27
Q4 2017	-$51M	-$18.3M	-$11.6M	-176%	Oct 1, 2017	Dec 31, 2017	10-K	2019-02-26
Q3 2017	-$39.4M	-$11.6M	-$4.36M	-60.5%	Jul 1, 2017	Sep 30, 2017	10-K	2019-02-26
Q2 2017	-$35M	-$12.1M	-$4.83M	-66.2%	Apr 1, 2017	Jun 30, 2017	10-K	2019-02-26
Q1 2017	-$30.2M	-$9.05M	-$3.05M	-50.9%	Jan 1, 2017	Mar 31, 2017	10-K	2019-02-26
Q4 2016	-$27.1M	-$6.62M			Oct 1, 2016	Dec 31, 2016	10-K	2018-03-19
Q3 2016		-$7.21M			Jul 1, 2016	Sep 30, 2016	10-K	2018-03-19
Q2 2016		-$7.29M			Apr 1, 2016	Jun 30, 2016	10-K	2018-03-19
Q1 2016		-$6M			Jan 1, 2016	Mar 31, 2016	10-K	2018-03-19

* An asterisk sign (*) next to the value indicates that the value is likely invalid.